Innate Pharma (IPHA) and the Institute for Follicular Lymphoma said Friday they have agreed to study the potential of the company's IPH6501 experimental therapy in follicular lymphoma, a type of blood cancer.
The company's ongoing phase 1/2 trial, which examines IPH6501 in relapsed/refractory non-hodgkin lymphoma, will now include patients with relapsed/refractory follicular lymphoma.
To support the inclusion of follicular lymphoma patients in the trial, the Institute for Follicular Lymphoma will initially invest $3 million into new shares of Innate.
The Institute for Follicular Lymphoma may invest an additional $4.9 million upon reaching certain milestones, the partners said.
Shares of Innate Pharma rose more than 12% in premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。